LIVALO Statin Lowers Hypercholesterolemia, Combined Dyslipidemia

 

August 4, 2009

LIVALO (pitavastatin), a potent HMG-CoA reductase inhibitor (statin) for the primary treatment of hypercholesterolemia and combined dyslipidemia, was approved by the FDA in August 2009.

LIVALO is a fully synthetic and highly potent statin engineered in Japan. LIVALO differs from other, currently available statins in the U.S. in that it has a unique cyclopropyl group on the base structure, the company said. This cyclopropyl group contributes to a more effective inhibition of the HMG-CoA reductase enzyme to inhibit cholesterol production, and potentially affords greater low-density lipoprotein cholesterol (LDL-C) clearance and reduction of plasma cholesterol. Pitavastatin is only minimally metabolized by the liver through the cytochrome P450 pathway, through which many other medications are metabolized.

The drug is available in three dosages (1 mg, 2 mg and 4 mg).

For more information: www.kowapharma.com